The Company's Biopharmaceuticals unit is engaged in research, development and commercial activities and its EDT unit focuses on product development, scale-up and manufacturing to address drug optimization challenges of the pharmaceutical industry.
View All Commentary (ELN)
Recs
postbusters (75.41) Submitted: 11/11/08 3:04 PM : Start Price: $6.68 ELN Score: 13.89
I've been following ELN for years and have been burned terribly, but each time the stock rises from the ashes to head for the stars. They have such a great success at innovative new treatments that I have to believe they will be back in the fight for the title again.
Report this Post Replies: 0 | Reply | Permalink
Oops! There appears to be a problem with your comment. Check to see if there's something you left out.
Terms & Conditions
RSS Headlines
Fool UK